PERJETA 420 MG CONCENTRADO PARA SOLUCION PARA PERFUSION

( ARTG ) Early Breast Cancer Perjeta is indicated in combination with trastuzumab and chemotherapy for:,- the neoadjuvant treatment of patients with HER2-positive inflammatory or locally advanced, or early stage (either > 2 cm in diameter or node positive) breast cancer as part of a complete treatment regimen for early breast cancer,-the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.,Metastatic Breast Cancer,Perjeta is indicated in combination with trastuzumab and docetaxel for patients with metastatic HER2-positive breast cancer who have not received prior anti-HER2 therapy or chemotherapy for their metastatic disease.